Zhejiang Jingxin Pharmaceutical Co Ltd (SHE:002020) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Jingxin Pharmaceutical Co Ltd (002020)
Zhejiang Jingxin Pharmaceutical Co Ltd (SHE:002020) has a market capitalization of $1.44 Billion (CN¥9.82 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #7435 globally and #1622 in its home market, demonstrating a -2.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Jingxin Pharmaceutical Co Ltd's stock price CN¥11.40 by its total outstanding shares 861029140 (861.03 Million). Also see 002020 total assets for a full breakdown of the balance sheet.
Zhejiang Jingxin Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang Jingxin Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.44 Billion to $1.44 Billion (0.35% CAGR). Also see Zhejiang Jingxin Pharmaceutical Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Zhejiang Jingxin Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Jingxin Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 002020 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.59x
Zhejiang Jingxin Pharmaceutical Co Ltd's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.15x
Zhejiang Jingxin Pharmaceutical Co Ltd's market cap is 3.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $977.75 Million | $1.88 Billion | $199.75 Million | 0.52x | 4.89x |
| 2017 | $1.00 Billion | $2.22 Billion | $264.38 Million | 0.45x | 3.79x |
| 2018 | $761.66 Million | $2.94 Billion | $369.28 Million | 0.26x | 2.06x |
| 2019 | $974.97 Million | $3.65 Billion | $520.40 Million | 0.27x | 1.87x |
| 2020 | $933.02 Million | $3.26 Billion | $653.07 Million | 0.29x | 1.43x |
| 2021 | $1.11 Billion | $3.47 Billion | $612.54 Million | 0.32x | 1.81x |
| 2022 | $1.47 Billion | $3.78 Billion | $662.25 Million | 0.39x | 2.21x |
| 2023 | $1.56 Billion | $4.00 Billion | $618.90 Million | 0.39x | 2.52x |
| 2024 | $1.61 Billion | $4.16 Billion | $711.96 Million | 0.39x | 2.27x |
| 2025 | $2.39 Billion | $4.07 Billion | $757.98 Million | 0.59x | 3.15x |
Competitor Companies of 002020 by Market Capitalization
Companies near Zhejiang Jingxin Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review Zhejiang Jingxin Pharmaceutical Co Ltd (002020) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Zhejiang Jingxin Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Zhejiang Jingxin Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Jingxin Pharmaceutical Co Ltd's market cap moved from $1.44 Billion to $ 1.44 Billion, with a yearly change of 0.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.44 Billion | -39.94% |
| 2025 | CN¥2.39 Billion | +48.28% |
| 2024 | CN¥1.61 Billion | +3.32% |
| 2023 | CN¥1.56 Billion | +6.45% |
| 2022 | CN¥1.47 Billion | +32.56% |
| 2021 | CN¥1.11 Billion | +18.56% |
| 2020 | CN¥933.02 Million | -4.30% |
| 2019 | CN¥974.97 Million | +28.01% |
| 2018 | CN¥761.66 Million | -23.94% |
| 2017 | CN¥1.00 Billion | +2.42% |
| 2016 | CN¥977.75 Million | -32.08% |
| 2015 | CN¥1.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Zhejiang Jingxin Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.44 Billion USD |
| MoneyControl | $1.44 Billion USD |
| MarketWatch | $1.44 Billion USD |
| marketcap.company | $1.44 Billion USD |
| Reuters | $1.44 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemi… Read more